Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Plus de 40 000 produits accessibles à 0€ de frais de courtage
Découvrir Boursomarkets
Retour au sujet GENOMICA CORP

GLBX GENOMC&BIOTECH : NEWS : Partenariat avec Mayo Clinic

13 févr. 201214:48

press release
Feb. 13, 2012, 8:00 a.m. EST

Mayo Clinic Selects Complete Genomics to Provide Outsourced Whole Genome Sequencing

MOUNTAIN VIEW, Calif., Feb 13, 2012 (GlobeNewswire via COMTEX) -- Complete Genomics Inc. /quotes/zigman/1318953/quotes/nls/gnom GNOM +9.42% announced today that it has been selected by Mayo Clinic's Center for Individualized Medicine to provide outsourced whole human genome sequencing. Mayo Clinic researchers will now be able to employ Complete Genomics' sequencing service for some of its large-scale whole genome sequencing projects.

The Center for Individualized Medicine operates a comprehensive sequencing laboratory in its own Medical Genome Facility, but it determined that collaboration with Complete Genomics could supplement the services available to its community of medical researchers. Under the terms of the agreement, Mayo Clinic can send genetic material to Complete Genomics for sequencing and analysis. It will continue to operate and invest in its Medical Genome Facility. Financial details of the agreement were not disclosed.

"Mayo Clinic, through the Center for Individualized Medicine, already has several high-impact genome- and epigenome-based studies underway in individualized care for our patients," said Gianrico Farrugia, M.D., director of Mayo Clinic's Center for Individualized Medicine. "Access to quality whole genome sequencing services can only expedite our efforts to improve care for all of our patients with new individualized medicine tools and techniques."

"It is exciting to see a world-renowned healthcare organization like Mayo Clinic take the next step towards bringing high-quality whole genome sequencing data into the clinic. They clearly recognize its potential to personalize treatment options and improve the future quality of patient care," said Leroy Hood, M.D., Ph.D., president of the Institute for Systems Biology and a member of Complete Genomics' Scientific Advisory Board. "This is a big step toward the realization of personalized medicine."

"For well over a century, Mayo Clinic has been an innovator and leader in translating cutting-edge clinical research into world-class patient care and treatment," said Clifford Reid, Ph.D., chairman, president and CEO of Complete Genomics. "We are honored to be partnering with Mayo Clinic researchers to provide sequencing and analysis for their genomic studies and investigations."

Projects will be coordinated with the Center of Individualized Medicine's Medical Genome Facility and will help expedite Mayo Clinic's translational genomics-based programs. Through these initiatives, Mayo Clinic will develop best practices for using genetic information to guide patient care.

Mayo's effort is part of a growing trend in medicine to collect and analyze the genetic information from consenting patients to optimize medical care in a variety of disciplines, including cancer diagnosis and treatment, drug therapy, disease prevention, and many others. This information could also be used by doctors to advise patients about lifestyle changes that could help prevent or delay disease onset.

About The Center for Individualized Medicine

The Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit or

About Complete Genomics

Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing service. The Complete Genomics Analysis Platform (CGA(TM) Platform) combines Complete Genomics' proprietary human genome sequencing technology with advanced informatics and data management software. Additional information can be found at .

The Complete Genomics logo is available at

This news release was distributed by GlobeNewswire,

SOURCE: Complete Genomics

2 réponses

  • 13 février 201215:12

    se passait car 4.03 USD en préouverture...
    8.600 titres à 2.86 USD yessss encore merci à toi....

  • 13 février 201216:30

    je comprends mieux ce qu'il se passe. Je viens d'ouvrir mon compte et j'avais trop d'argent tout à coup :)
    Sympa de partager l'info

Retour au sujet GENOMICA CORP

Mes listes

Cette liste ne contient aucune valeur.